Oppenheimer analyst Leland Gershell maintains $Biomarin Pharmaceutical (BMRN.US)$ with a hold rating.
According to TipRanks data, the analyst has a success rate of 37.7% and a total average return of 4.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Biomarin Pharmaceutical (BMRN.US)$'s main analysts recently are as follows:
BioMarin delivered a robust financial quarter, with a slight increase in its guidance for both revenue and earnings. The valuation of the company's enzyme replacement therapy business is believed to be equal to or greater than the current trading level of the company's shares. The anticipation for BMN333, which is slated to enter clinical trials in early 2025, is high as it has the potential to be a major factor in maintaining market share in achondroplasia and may expand to additional indications where Voxzogo is under investigation.
BioMarin's quarterly financial outcomes indicated a surpassing of estimated top and bottom lines, with a modest increase in the fiscal 2024 forecast for all principal indicators. Analysts note that although Voxzogo's performance was below expectations, this shortfall was compensated by the stronger than anticipated outcomes from various offerings within the company's enzyme replacement therapy portfolio.
The assessment notes an appealing entry point for BioMarin at the current share value, highlighting the company's solid foundational business and the possibility for significant operating margin growth in the upcoming years.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.